
Downloaded from
https://kar.kent.ac.uk/72762/ The University of Kent's Academic Repository KAR

The version of record is available from
https://doi.org/10.1136/bmj.l744

This document version
Publisher pdf

DOI for this version

Licence for this version
UNSPECIFIED

Additional information

Versions of research works

Versions of Record
If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

Author Accepted Manuscripts
If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in *Title of Journal*, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).

Enquiries
If you have questions about this document contact ResearchSupport@kent.ac.uk. Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies).
Improving the evidence base for social prescribing

Kate E Hamilton-West reader in health psychology, faculty director of medical social sciences, Erica Gadsby senior research fellow, Sarah Hotham research fellow

Centre for Health Services Studies, University of Kent, Canterbury CT2 7NF, UK

Salisbury’s article raises important points about the widespread rollout of social prescribing. Linking people with services that could help tackle problems that contribute to reduced wellbeing seems sensible, but the approach rests on several problematic assumptions.

A recent systematic review concluded that current evidence on social prescribing is insufficient to judge either success or value for money. Of the 15 evaluations identified, most were small scale and limited by poor design and reporting. Studies on patient and referrer experience mainly reported positive findings but showed limited understanding or familiarity with social prescribing.

We used evaluability assessment to examine social prescribing programmes and reported on the lessons we learnt. These included ensuring that programmes are designed with stakeholder involvement and buy-in; that information governance and data sharing agreements are in place from the start; that staffing levels are sufficient to cover the range of activities involved in service delivery and monitoring; that social prescribing programmes are co-located with primary care; and that linkage to health service data systems is established as part of the programme design.

NHS England is working to improve the evidence base for social prescribing, including funding 23 projects through the health and wellbeing fund to find out which models work best and developing resources to support the implementation and evaluation of social prescribing programmes. Gaps in the evidence base could also be filled by planning programmes more systematically, with evaluation frameworks developed through collaboration between those involved in developing, delivering, participating in and evaluating the programmes.

To realise the potential benefits of social prescribing for patients, general practitioners, and the NHS, the underlying assumptions must be made explicit, and research efforts should be targeted towards these. We have proposed a list of assumptions as the starting point for taking this work forward.

Competing interests: None declared.

Full response at: https://www.bmj.com/content/364/bmj.l271/rr-1

1 Salisbury H. Helen Salisbury: Social prescribing and the No 17 bus. BMJ 2019;364:l271. 10.1136/bmj.l271 30679174

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

k.e.hamilton-west@kent.ac.uk